| M.MucoMax® | |
|---|---|
| Cervical cancer |
Stable constant high-manifestation vector for cervical cancer treatment vaccines and recombinant lactic acid bacteria that has been transformed by the vector
|
| Muscular dystrophy |
Cell surface display vector that manifests myostatin and microorganisms that have been transformed by the vector
|
|
Fusion protein surface display vector of Myo-2 peptide composition, and myostatin and microorganisms that have been transformed by the vector
|
|
| Manifestation (Promoter) |
New constant, high-manifestation promoter and its purpose of use
|
| Transporter (PKV Vector) |
Constant high-manifestation vector containing repE rogue genes
|
| Display |
Surface display vector using γ-PGA synthetic genes originating from the Bacillus strain and the method of using this to manifest the surfaces of microorganisms of a protein
|
| H.HumaMax® | |
|---|---|
| CIN1 |
Use of γ-PGA in the treatment of cervical epithelium dysmorphia
|
| Vaccine adjuvant |
Immunoadjuvant composition containing γ-PGA and keto acid nanoparticles
|
|
Vaccine containing either γ-PGA-keto acid-sM2HA2 nanoparticles or γ-PGA-keto acid-sM2HA2CTA1 nanoparticles
|
|